pCMV6-XL4 ASXL1 (p.G646 Wfs *12) 3x FLAG
(Plasmid
#74245)
-
PurposeCancer-associated ASXL1 truncation mutant in mammalian expression vector
-
Depositing Lab
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 74245 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepCMV6-XL4
-
Backbone manufacturerOrigene
- Backbone size w/o insert (bp) 7000
- Total vector size (bp) 9000
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameASXL1
-
Alt nameadditional sex combs like 1, transcriptional regulator
-
SpeciesH. sapiens (human)
-
Insert Size (bp)2000
-
Mutationp.G646 Wfs *12 truncation
-
Entrez GeneASXL1 (a.k.a. BOPS, MDS)
- Promoter CMV
-
Tag
/ Fusion Protein
- 3X FLAG (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site NotI (unknown if destroyed)
- 3′ cloning site EcoRI (unknown if destroyed)
- 5′ sequencing primer CMV-F
- 3′ sequencing primer hGH-pA-R (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pCMV6-XL4 ASXL1 (p.G646 Wfs *12) 3x FLAG was a gift from Anjana Rao (Addgene plasmid # 74245 ; http://n2t.net/addgene:74245 ; RRID:Addgene_74245) -
For your References section:
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Balasubramani A, Larjo A, Bassein JA, Chang X, Hastie RB, Togher SM, Lahdesmaki H, Rao A. Nat Commun. 2015 Jun 22;6:7307. doi: 10.1038/ncomms8307. 10.1038/ncomms8307 PubMed 26095772